Abstract

Abstract Background and Aims Hemoglobin decrease and anemia are common in chronic kidney disease (CKD). This study aimed to evaluate hemoglobin variability in patients with CKD according to decline in kidney function. Method We analyzed patients from the KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD). The rates of renal function decline per year were determined using the slope of estimated glomerular filtration rate (eGFR) analyzed using a generalized linear mixed model. Rapid decline in kidney function was defined as a decline in the eGFR of >3 mL/min/1.73 m2/year. Hemoglobin value was measured at 0, 6, and 12 month and annually for up to 8 years. Hemoglobin variability was calculated by standard deviation. Higher hemoglobin variability was defined as a hemoglobin variability value greater than the median. Results Among 1895 patients, 736 patients (38.8%) were in the rapid kidney function decline group. In 1472 patients who were 1:1 propensity score-matched, the baseline eGFR was not significantly different between the non-rapid and rapid kidney function decline groups (48.2 ± 26.9 vs 46.9 ± 26.2 ml/min/1.73m2, P = 0.345). The use of iron supplements (P = 0.536) or erythropoiesis stimulating agents (P = 0.699) was similar in both groups. In multivariable logistic regression analysis, rapid decline in kidney function was significantly associated with higher hemoglobin variability (odds ratio [OR]: 1.81; 95% confidence interval [CI]: 1.43–2.28; P < 0.001). This association was prominent in the group without anemia at baseline (OR: 2.82; 95% CI: 1.99–4.01; P < 0.001). Conclusion Rapid decline in kidney function is associated with higher hemoglobin variability in patients with CKD. Attention should be paid to hemoglobin variability in patients with a rapid decline in kidney function.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call